SEC Form 4 · accession 0001894117-26-000006
Maze Therapeutics, Inc. · MAZE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sophie Kornowski
Director
Period of report
Aug 13, 2026
Accepted (ET)
Aug 17, 2026 · 4:52 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001842295
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $27.665 | Aug 13, 2026 | A | 36,000 | A | — | Aug 12, 2036 | Common Stock | 36,000 | 36,000 | D |
Explanation of responses
- F1The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.